 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Alteon Inc.
 |
Alteon Inc. |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
Slash and Burn at Nortel
Jun 15 2001 11:22 AM PDT
PROFILE |
 |
Alteon is breaking the AGE barrier. The development-stage pharmaceutical company's drugs are designed to inhibit or block damage caused by advanced glycosylation end-products (AGE), which are the result of elevated levels of glucose. Its drug candidates, based on the compound pimagedine, treat such complications of diabetes as diabetic kidney disease and end-stage renal disease. Alteon seeks a partner to continue pimagedine's development for Type I diabetes. It is also testing ALT-711, which breaks protein crosslinks that may inhibit cardiovascular disease; the drug may also have other indications. The firm's development and marketing partners include Roche, Yamanouchi Pharmaceutical, and IDEXX Laboratories.
COMPETITION |
 |
Amylin Pharmaceuticals, Inc. (AMLN)
CollaGenex Pharmaceuticals, Inc. (CGPI)
DEALS |
 |
Deal: Alteon Allies with Sun and Intel
Date Announced: 10.12.00
Value of transaction (US $Mil): 0
Description: Three giants join Content Bridge alliance formed by Inktomi, Adero, others.
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.60
1-Yr. Sales Growth: (60.3)%
Employees: 26
Revenue per employee: $23,076.92
KEY PEOPLE |
 |
Kenneth I. Moch
CEO
Elizabeth A. O'Dell
CFO
CONTACT INFO |
 |
170 Williams Dr.
Ramsey, NJ 07446
US
Phone: 201-934-5000
Fax: 201-934-8880
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |